- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Pertuzumab – March 2019
Pertuzumab: Solution for I.V. infusion 420 mg in 14 mL; Perjeta®
Last updated
5 July 2019